

LISTING OF THE CLAIMS

The following listing of the claims will replace all prior versions, and listings, of claims for this application.

1. **(currently amended)** A method for treating a patient suffering from or predisposed to developing ~~an inflammatory disorder~~ alveolitis and interstitial lung disease (ILD), comprising administering to the patient a pharmaceutical formulation that comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs or analogs thereof, and combinations of any of the foregoing.

2. **(original)** The method of claim 1, wherein the active agent is *cis*-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.

3. **(original)** The method of claim 2, wherein the active agent is *cis*-resveratrol.

4. **(original)** The method of claim 2, wherein the active agent is a conjugate of *cis*-resveratrol and a mono- or di-saccharide.

5. **(original)** The method of claim 4, wherein the active agent is *cis*-resveratrol glucoside.

6. **(original)** The method of claim 1, wherein the active agent is *trans*-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.

7. **(original)** The method of claim 6, wherein the active agent is *trans*-resveratrol.

8. **(original)** The method of claim 6, wherein the active agent is a conjugate of *trans*-resveratrol and a mono- or di-saccharide.

9. **(original)** The method of claim 8, wherein the active agent is *trans*-resveratrol glucoside.

10. **(original)** The method of claim 1, wherein the active agent comprises a mixture of *cis*-resveratrol and *trans*-resveratrol.

11. **(original)** The method of claim 1, wherein the active agent is delivered orally.

12. **(original)** The method of claim 1, wherein the active agent is delivered by pulmonary administration.

13. **(original)** The method of claim 1, wherein the active agent is delivered parenterally.

14. **(original)** The method of claim 13, wherein the active agent is delivered to the alveoli.

15-22. **(canceled)**

23. **(original)** The method of claim 22, wherein the organic or inorganic dust is derived from one or more materials selected from the group consisting of silica, asbestos, beryllium, coal, carbon, wood, starch, sugar, flour, synthetic polymers, cellulosic materials, clay concrete, lime and earth.

24. **(original)** The method of claim 1, further comprising the co-administration of an additional active agent.

25. **(original)** The method of claim 24, wherein the formulation further includes an additional active agent.

26. **(original)** The method of claim 25, wherein the additional active agent is selected from the group consisting of glucocorticoids, non-steroidal antiinflammatory drugs, macrolide antibiotics, bronchodilators, leukotriene receptor inhibitors, cromolyn sulfate and combinations thereof.

27. **(previously amended)** The method of claim 26, wherein the additional active agent is selected from the group consisting of phosphodiesterase inhibitors, long acting β_2 adrenergic agonists, and combinations thereof.

28. **(original)** The method of claim 27, wherein the additional active agent is selected from the group consisting of theophylline, salmetrol xinafoate, and a combination thereof.

29. **(currently amended)** A pharmaceutical formulation for pulmonary administration for treatment of ~~an inflammatory respiratory disorder~~ alveolitis and interstitial lung disease (ILD), comprising a first active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs or analogs thereof, and combinations of any of the foregoing, and a second active agent selected from the group consisting of glucocorticoids, non-steroidal antiinflammatory drugs, macrolide antibiotics, bronchodilators, and combinations thereof, and a carrier suitable for pulmonary drug administration.

30. **(currently amended)** ~~A dry powder~~ The pharmaceutical formulation for pulmonary administration, comprising an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and a carrier suitable for pulmonary drug administration of claim 29, in the form of a dry powder.

31. **(currently amended)** A pharmaceutical formulation for treatment of ~~an inflammatory respiratory disorder~~ alveolitis and interstitial lung disease (ILD) comprising a first active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs or analogs thereof, and combinations of any of the foregoing, and a second active agent selected from the group consisting of glucocorticoids, bronchodilators, leukotriene receptor inhibitors, cromolyn sulfate and combinations thereof.

32. **(previously added)** The formulation of claim 31, wherein the formulation further comprises a carrier suitable for pulmonary drug administration, and the formulation is administered via inhalation.

33. **(previously added)** The formulation of claim 31, wherein the formulation is administered orally or parenterally.

34. **(canceled)**

35. **(previously added)** The dry powder formulation of claim 30, wherein the carrier is a pharmaceutical sugar.

36. **(previously added)** The dry powder formulation of claim 30, wherein the particles of the powder have a diameter from about 0.1 μm to about 65 μm .

37. **(canceled)**

38. **(new)** The pharmaceutical formulation of claim 1, wherein the ILD is fibrosing alveolitis, sarcoidosis, or fibrotic lung disease.

B² cont
39. **(new)** The pharmaceutical formulation of claim 29, wherein the ILD is fibrosing alveolitis, sarcoidosis, or fibrotic lung disease.

40. **(new)** The pharmaceutical formulation of claim 31, wherein the ILD is fibrosing alveolitis, sarcoidosis, or fibrotic lung disease.
